Schiff Nutrition International, Inc. Makes Key Appointments to Scientific Advisory Board
December 01 2011 - 8:00AM
Business Wire
Schiff Nutrition International, Inc., (NYSE: WNI), announced
today it has appointed three new members to its
recently-established Scientific Advisory Board: Dale Bredesen, MD;
Michael A. Fischbach, Ph.D.; and Charles N. Serhan, Ph.D. Dr.
Richard H. Carmona, 17th Surgeon General of the United States,
currently serves as chair of the Scientific Advisory Board.
Tarang Amin, president and chief executive officer of Schiff
Nutrition, stated: “The Scientific Advisory Board has been
established to play a key role in our efforts to lead innovation.
These three additions strengthen and diversify the expertise from
which to draw as we pursue new product development. We look forward
to the guidance of Dr. Bredesen in aging and age-associated
diseases, Dr. Fischbach in probiotics and Dr. Serhan in
inflammation. This is all complemented by Dr. Carmona’s background
as one of the world’s leading experts in public health.”
Dale Bredesen, MD is Professor and Founding President of the
Buck Institute for Age Research, the nation’s only independent
research institute focused on aging and age-associated disease, and
Adjunct Professor, Department of Neurology, UCSF. Dr. Bredesen is a
member of the National Advisory Council on Aging, the Society for
Neuroscience, and the American Society for Biochemistry and
Molecular Biology. He has co-authored over 180 scientific papers
and three books. He received his undergraduate degree from Caltech
and his MD from Duke University School of Medicine.
Michael Fischbach, Ph.D. is an Assistant Professor in the
Department of Bioengineering and Therapeutic Sciences at UCSF and a
member of the California Institute of Quantitative Biosciences.
Fischbach is a recipient of the NIH Director's New Innovator Award,
a Fellowship for Science and Engineering from the David and Lucille
Packard Foundation, a Medical Research award from the W.M. Keck
Foundation, and the Young Investigator Grant for Probiotics
Research from the Global Probiotics Council. Fischbach worked
at Harvard University in the laboratories of Christopher Walsh and
David Liu and spent two years as an independent fellow at
Massachusetts General Hospital coordinating a collaborative effort
based at the Broad Institute to develop genomics-based approaches
to the discovery of small molecules from microbes. Fischbach
received his Ph.D. in chemistry from Harvard University.
Charles N. Serhan, Ph.D. is the Simon Gelman Professor of
Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard
Medical School, a Professor in the Department of Oral Medicine,
Infection and Immunity at Harvard School of Dental Medicine and an
Affiliate Faculty Member of MIT. Dr. Serhan was appointed to the
Harvard Faculty in 1986 and has served as Senior Biochemist in
Medicine at Brigham and Women’s Hospital since 1992. An author of
346 publications, he has received a number of awards and honors,
including a MERIT Award from the National Institute of General
Medical Sciences and an honorary degree from Harvard University.
Dr. Serhan received degrees in Biochemistry from Stony Brook
University, Experimental Pathology and Medical Sciences at the New
York University School of Medicine, as well as post-doctoral
training in Physiological Chemistry at the Karolinska Institute
Medical University in Stockholm, Sweden.
About Schiff Nutrition
Schiff Nutrition International, Inc. develops, manufactures,
markets and distributes branded and private label vitamins,
nutritional supplements and nutrition bars in the United States and
throughout the world. Schiff’s portfolio of well-known brands
includes Schiff Move Free®, Schiff® Vitamins, Schiff MegaRed®,
Schiff Mega-D3®, Tiger's Milk®, Schiff Sustenex®, and Schiff
Digestive Advantage®. To learn more about Schiff, please visit the
web site www.schiffnutrition.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that are based
on management’s beliefs and assumptions, current expectations,
estimates, and projections. These statements are subject to known
and unknown risks and uncertainties, certain of which are beyond
the company’s ability to control or predict, and therefore, actual
results may differ materially. Any forward-looking statements are
made pursuant to the Private Securities Litigation Reform Act of
1995 and, as such, speak only as of the date hereof. Schiff
Nutrition disclaims any obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise. You are cautioned not to place undue reliance on these
forward-looking statements.
Important factors that may cause actual results of Schiff
Nutrition to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited to:
members of our Scientific Advisory Board may not continue service,
dependence on sales of Schiff Move Free product and the joint care
category, dependence on sales of Schiff MegaRed product, dependence
on individual customers, adverse publicity or consumer perception
regarding our nutritional supplements and/or their ingredients,
similar products distributed by other companies or the nutritional
supplement industry generally, the impact of competitive products
and pricing pressure (including expansion of private label
products), the inability to successfully bid on new and existing
private label business, the impact of raw material pricing,
availability and quality (particularly relating to joint care
products and ingredients from third-party suppliers outside the
United States, including China), claims that our products infringe
the intellectual property rights of others, the inability to
enforce or protect our intellectual property rights and proprietary
techniques against infringement, the inability to successfully
launch and maintain sales (especially in the joint care and omega-3
categories) outside of the United States while maintaining the
integrity of the products sold and complying with local
regulations, the inability to appropriately respond to changing
consumer preferences and demand for new products, the inability to
gain or maintain market distribution for new products or product
enhancements, including products in the probiotic space, litigation
and government or administrative regulatory action in the United
States and internationally, including FDA enforcement and product
liability claims, the inability or increased cost to obtain
sufficient levels of product liability and general insurance, the
inability to comply with existing or new regulations, both in the
United States and abroad, and adverse actions regarding product
formulation, claims or advertising, product recalls or a
significant amount of product returns, dependence on a single
manufacturing facility and potential disruptions of our
manufacturing operations, the inability to find strategic
transaction opportunities or the inability to successfully
consummate or integrate a strategic transaction (including the
inability to successfully integrate the assets recently acquired
from Ganeden), the inability to maintain or attract key personnel,
interruptions to our information technology systems, control by our
principal stockholders, and other factors indicated from time to
time in the company’s SEC reports, copies of which are available
upon request from the company’s investor relations department or
may be obtained at the SEC's web site (www.sec.gov). These risks and uncertainties should
be carefully considered before making an investment decision with
respect to shares of our common stock.
Schiff Nutrit (NYSE:WNI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Schiff Nutrit (NYSE:WNI)
Historical Stock Chart
From Oct 2023 to Oct 2024